Please provide your email address to receive an email when new articles are posted on . Lyu and colleagues analyzed electronic medical records data from 151 adults aged at least 45 years identified as ...

BOUCHERVILLE, Quebec, Feb. 20, 2024 (GLOBE NEWSWIRE) -- Sandoz Canada is pleased to announce that Health Canada has provided authorization to market Jubbonti ® (denosumab subcutaneous injection, ...

(RTTNews) - Biocon Biologics Ltd., a fully integrated global biosimilars company and subsidiary of Biocon Ltd., announced Wednesday that the U.S. Food and Drug Administration (FDA) has approved Bosaya ...

The FDA said it's looking into the risk of severe hypocalcemia among patients on dialysis receiving denosumab (Prolia), citing the potential for severe outcomes, including hospitalization and death.

Subcutaneous (subQ or SQ) injections are shots given in the fatty tissue layer (subcutaneous fat) under your skin. Your skin has many layers, and the subcutaneous layer is beneath the epidermis and ...

Question: I changed my insurance for 2026 and I am having trouble with my Prolia shot – what are my options? Answer: First let me explain what Prolia is for those that may not know. Prolia is a ...

Jubbonti ® (denosumab-bbdz) and Wyost ® (denosumab-bbdz), interchangeable biosimilars to Prolia ® (denosumab) and Xgeva ® (denosumab), respectively, are now available from Sandoz. The ...

SHANGHAI, Dec. 16, 2025 /PRNewswire/ -- Mabwell (688062.SH), an innovative biopharmaceutical company with an integrated industry chain, announced that it has completed the first commercial shipment of ...

Changes in Invasive Breast Cancer and Ductal Carcinoma In Situ Rates in Relation to the Decline in Hormone Therapy Use Patients were randomly assigned to receive either subcutaneous denosumab 120 mg ...

The FDA approved Stoboclo and Osenvelt, denosumab biosimilars that could offer more affordable treatment options for osteoporosis and bone loss in various patient populations. Stoboclo and Osenvelt ...

Please provide your email address to receive an email when new articles are posted on . The FDA is investigating the risk of severe hypocalcemia in patients on dialysis treated with the osteoporosis ...